Frequently Asked Questions

FAQ 1: If StromaGenesis is so good, why did it take so long? ▼

Because the science required nearly two decades of NIH-funded research & development. The assets were temporarily inside a company that did not commercialize them, and only in recent years did ownership, validation, and regulatory conditions fully align.

Long Answer (Full Investor-Grade Version)

The underlying biology required ~18 years of NIH-funded research & development
CCR5 biology, Cav-1 stromal signaling, metastasis modeling, and outcome-linked gene signatures all required long-term research and validation across multi-center cohorts.
Human clinical validation takes years by definition
SG’s algorithm was validated in U.S., Canadian, and European datasets, using matched biopsy–prostatectomy samples with long-term metastasis follow-up.
The assets spent years inside a company that lacked diagnostic capabilities
The prior owner was therapeutic-focused and had no CLIA, diagnostic commercialization team, or payer strategy.
The regulatory environment changed
StromaGenesis can now launch via CLIA LDT, a pathway not mature when the original science was done.
The oncology field had to “catch up”
Tumor microenvironment (TME) biology, fibrosis science, and AI-based diagnostics only recently became mainstream.
The time invested now creates SG’s moat
Deep biology + long-term datasets + patented algorithm = an advantage competitors cannot replicate.

FAQ 2: Does Dr. Richard Pestell have the experience to lead a multi-million-dollar Biotech company? ▼

Yes. Dr. Pestell he has already founded and exited multi-million-dollar companies, he has run multi-billion-dollar health systems, directed major NCI-designated cancer centers, overseen more clinical trials than nearly any diagnostic CEO in the world, and is now surrounded by a commercialization-focused team built specifically to ensure operational success. His background is far closer to a biotech CEO than that of a career academic.

Long Answer (Full Investor-Grade Version)

Because Dr. Pestell has already founded and successfully exited biotechnology companies
Unlike most academic founders who have never commercialized anything, Dr. Pestell has a documented entrepreneurial track record:

> Founder of ProstaGene (sold in 2018 for 27M CYDY shares)
> Founder of LightSeed
> Founder of EcoGenome

Dr. Pestell has repeatedly demonstrated the essential startup CEO competencies:

> Building companies
> Raising capital
> Transferring intellectual property
> Scaling early scientific teams
> Completing transactions and exits
> Navigating diligence and investor evaluations

This already places him in the top 1% of academic scientists in terms of real commercial execution.
Because Dr. Pestell has already managed organizations far larger and more complex than any startup CEO ever will.

As Executive Vice President of Thomas Jefferson University, Pestell helped operate:

> An 11-hospital system
> With a $5.6 billion annual budget
> With more than 30,000 employees

Running StromaGenesis, even at scale, is dramatically smaller in operational complexity than what he has already overseen. Most startup CEOs have never managed a multi-billion-dollar operating environment coordinated across hospitals, clinical departments, research institutes, and compliance divisions, overseen enterprise-level budgets or strategic restructuring. Dr. Pestell has done all of this for years.
Because Dr. Pestell’s scientific authority creates immediate credibility with physicians, payers, and pharma.

In diagnostics, physician trust is everything.

Dr Pestell’s credentials:
> H-index 158 (top 0.01% globally)
> 57 peer-reviewed publications directly relevant to SG’s diagnostic platform
> 30 issued / 4 patent pending
> Dr Pestell is a pioneer of CCR5 and Cav-1 microenvironment biology
> Dr. Pestell is internationally recognized as a preeminent prostate cancer researcher

When StromaGenesis enters the market, physicians will immediately respect the scientific foundation, something competitors cannot match.
Because he has led two major National Cancer Institute (NCI)-designated cancer centers

This is not academic administration — this is running a highly regulated, translational ecosystem that mirrors the operational complexity of a biotech company.

Dr. Pestell has already served as:

> Director, Lombardi Comprehensive Cancer Center (Georgetown University)
> Director, Sidney Kimmel Cancer Center (Thomas Jefferson University)

Running an NCI-designated cancer center requires overseeing hundreds of clinical trials, managing FDA and NIH interactions, leading multi-disciplinary research programs, maintaining compliance for human subject research, directing translational and precision-medicine initiatives, budget stewardship, and recruiting and managing elite physician-scientists.

This is the closest real-world analog to running a precision-oncology biotech company.
Because SG includes elite FDA leadership that neutralizes the typical “scientist-to-CEO” risk

StromaGenesis did not rely solely on a scientific CEO. It intentionally built a regulatory backbone to support him, including:

Dr. Alberto Gutierrez, former Director, FDA Office of In Vitro Diagnostics (1992–2017)

This gives StromaGenesis unparalleled regulatory credibility, validation of SG’s diagnostic architecture, insight into proper LDT implementation, future FDA pathway optionality, and elimination of early-stage regulatory missteps.

Investors often fear that academic founders do not understand FDA. In StromaGenesis’s case, this concern is eliminated.
Because Pestell has personally overseen more than 120 Phase I, II, and III clinical trials

This level of clinical trial experience is extraordinarily rare for a diagnostic founder. Clinical trial oversight requires understanding clinical endpoints, managing patient recruitment, interfacing with CROs, IRBs, and FDA, interpreting data for regulatory submission, designing biomarker-driven trials, and ensuring statistical reliability.

Even though ProstaGene and SG’s diagnostics use the LDT pathway (no Phase trials required), the expertise translates directly into payer evidence development, clinical utility studies, KOL engagement, future companion diagnostic trials, and therapeutic prediction validation.

Most CEOs of Decipher, Oncotype, and Prolaris-era companies did not come in with this level of clinical command.
Because StromaGenesis built a “CEO surround” to complement Pestell’s scientific strengths
SG was intentionally structured so that Pestell focuses on:

> Scientific leadership
> Clinical interpretation
> Investor credibility
> Strategic direction
> IP evolution
> Partnerships with major cancer centers
> Alignment with FDA and payer expectations

Meanwhile, the operational load is carried by Commercial & Diagnostic Operations, former Eurofins leadership, that are high-volume CLIA operations experts, Almac Group for assay development, and global reimbursement strategists.

Regulatory
FDA IVD leadership with 25 years of experience

Technology & Data
> Bioinformatics teams
> AI/ML modeling teams
> CLIA workflow specialists

This means he does not need to be the “do-everything” CEO. He needs to be — and is — the scientific and clinical anchor around which the company scales.

Dr Pestell’s career path looks more like a biotech operator than a university professor. StromaGenesis does not have a “scientist-founder problem.” StromaGenesis has a founder who is uniquely suited for this moment in precision oncology.

FAQ 3: If the StromaGenesis IP is so strong, why didn’t a larger company commercialize it? ▼

Because StromaGenesis is the first company to acquire & consolidate EVERYTHING into one operational platform. The patents, algorithm, datasets, tumor microenvironment biomarkers, and commercialization capability, all, into one operational platform. StromaGenesis is the first and only entity with the complete platform and the operational ability to execute.

Long Answer (Full Investor-Grade Version)

Because big companies don’t build groundbreaking new diagnostics — they buy them

Every major diagnostic in the last 20 years was acquired, not internally built:

> Decipher (acquired for $600M)
> Oncotype DX (Genomic Health → $2.8B acquisition by Exact Sciences)
> Foundation Medicine (Roche acquisition: $5.3B)

SG fits this pattern. The reason no one else commercialized SG’s IP is simple:
Only the innovator can build it / Only the incumbents can buy it.
Because the foundational discoveries were scattered across multiple academic institutions for nearly two decades.

SG’s core biomarkers and gene signatures were generated across:

> Georgetown University
> Thomas Jefferson University
> UTSW
> NYU
> EU prostate cancer consortia
> Cedars-Sinai

Academic labs excel at scientific discovery — not commercialization.

They do not build CLIA assays, assemble payer strategies, conduct market-entry execution, manage IP consolidation, and run commercial diagnostics operations.

Large companies could not commercialize what no single entity controlled.
Because StromaGenesis’s algorithmic sophistication cannot be reverse-engineered

SG’s algorithm depends on:

> Proprietary weighting
> Private datasets
> Matched biopsy–prostatectomy cohorts
> Long-term metastasis outcomes
> Mechanistic CCR5 / Cav-1 integration
> Trade-secret modeling

Without SG’s internal datasets, duplication is impossible.
Because the market needed to evolve before the platform became commercially viable

Ten years ago, the prostate cancer diagnostic landscape was dominated by Decipher, Oncotype, Prolaris.

No one understood or valued:

> Tumor microenvironment biology
> Stromal fibrosis
> CCR5 migration mechanics
> Cav-1 architectural signaling
> AI-driven multi-modal algorithms

Today, these are among the most important concepts in oncology. StromaGenesis is perfectly timed with the market.

FAQ 4: Can larger, better-funded companies copy SG or move it aside? ▼

No. StromaGenesis’s patents, trade-secret algorithm, proprietary multi-center datasets, tumor microenvironment biology, and mechanistic AI integration form a moat that cannot be replicated. The biologic and algorithmic depth took nearly 20 years to develop and cannot be reconstructed by competitors.

Long Answer (Full Investor-Grade Version)

Because SG’s patent coverage is broad, international, and mechanistically anchored

SG holds issued patents covering:

> CCR5 diagnostic applications
> Cav-1 fibrosis & tumor microenvironment biology
> Gene signatures and prognostic classifiers
> Methods of assessing metastasis risk
> Therapeutic and companion diagnostic use cases

These patents extend across: U.S., EU, Canada & Japan, with additional Nationalized filings

These are not superficial patents — they are mechanistic and biologically central.
Because the algorithm CANNOT be reverse-engineered

StromaGenesis’s algorithm uses:

> Multi-layer weighting
> Interaction matrices
> Outcome-linked coefficients
> Proprietary datasets
> Nonlinear risk modeling
> TME and tumor-cell integration

This cannot be reconstructed from published papers.
Because StromaGenesis’s biology is based on mechanistic tumor microenvironment science that others missed

SG uniquely integrates tumor + stroma, including:

> CCR5-driven migration biology
> Cav-1 fibrosis and matrix remodeling
> Immune exclusion dynamics
> Microenvironment-driven treatment resistance

These pathways are first-in-class and protected by patents.
Because StromaGenesis’s AI integrates biological mechanisms, not generic machine learning SG’s platform models:

> Stromal resistance
> Metastatic activation signals
> Immune infiltration pathways
> Tumor architectural biology

This is not an expression assay. This is a biological intelligence system, built over nearly 20 years.
Because StromaGenesis’s advantage grows over time

Once launched, StromaGenesis will accumulate:

> Clinical utility data
> Payer impact evidence
> Physician adoption
> Therapeutic prediction datasets
> Outcomes-linked machine-learning refinement

The business / financial moat becomes self-reinforcing.
Because large companies are more likely to acquire StromaGenesis than compete with it

This is the historical pattern in diagnostics. StromaGenesis is positioned as the technological outlier with superior performance, with first-in-class biology, with mechanistic AI, and unmatched scientific credibility.

Competitors don’t replicate platforms like this — they buy them.

FAQ 5: Is the AI division real or just hype? ▼

It is absolutely real. StromaGenesis’s AI engine is the product of nearly 20 years of mechanistic cancer biology, validated in multiple international cohorts, driven by proprietary datasets, and essential to SG’s superior performance. This is not marketing—this is the core intellectual property of the entire diagnostic platform.

Long Answer (Full Investor-Grade Version)

Because the AI is built on mechanistic cancer biology, not generic machine learning StromaGenesis’s AI incorporates:

> CCR5 migration pathways
> Cav-1 fibrosis biology
> Tumor–stromal interaction networks
> Immune exclusion modeling
> Metastatic activation signatures

This is mechanistic modeling — not black-box AI.
Because SG’s AI integrates tumor + microenvironment biology, all competitors (Decipher, Prolaris, Oncotype) analyze only tumor cells.

StromaGenesis models:

> Tumor epithelium
> Stromal fibroblasts
> Extracellular matrix remodeling
> Immune cell trafficking
> Fibrosis gradients

This dual-domain modeling is years ahead of existing tests.
Because the AI is validated across independent human cohorts

StromaGenesis’s algorithm is validated in:

> Multi-center U.S. cohorts
> Canadian prostate cancer datasets
> European consortia
> BRCA2-enriched samples
> Biopsy–prostatectomy matched cohorts

This is not simulation — this is clinical reality.
Because the AI outperforms every commercial competitor

StromaGenesis’s hazard ratios and predictive performance exceed that of Decipher, Prolaris, Oncotype and Polygenic risk scores.

The only explanation for this level of performance is the depth of the algorithm.
Because the AI enables therapeutic prediction

SG’s platform can model:

> Treatment response likelihood
> Metastasis risk under therapy
> Microenvironmental resistance
> Drug penetration probability
> Combination therapy optimization

This moves SG beyond diagnostics into therapeutics.
Because the AI architecture is extensible to multiple cancers

StromaGenesis can expand into:

> Colon
> Breast
> Pancreatic (high fibrosis)
> Lung
> Melanoma

Wherever fibrosis or TME biology matters, SG’s AI has an advantage.
Because the algorithm is protected by trade secrets and proprietary datasets

No competitor can replicate StromaGenesis’s:

> Training data
> Stromal modeling factors
> Weighting matrices
> Non-linear classifiers
> Outcome-linked coefficients

This is the core moat that protects the entire operation.
Because AI is not an add-on. It is the product ProstaGene that is fundamentally an AI-driven biological engine. This is the intellectual center of StromaGenesis.

FAQ 6: Why will doctors switch from Decipher, Prolaris, and Oncotype to ProstaGene? ▼

Because ProstaGene is more accurate, models tumor microenvironment biology competitors entirely miss, provides meaningful advantages in Active Surveillance decisions, and requires zero workflow disruptions. Physicians adopt tests that materially improve patient outcomes, and ProstaGene does exactly that.

Long Answer (Full Investor-Grade Version)

Because ProstaGene delivers superior predictive accuracy

StromaGenesis’s algorithm outperforms Decipher, Prolaris and Oncotype across:

> Metastasis prediction
> Biochemical recurrence
> Long-term outcomes
> High-risk transformation

Clinical superiority drives adoption.
Because ProstaGene dramatically improves Active Surveillance decision-making - Active Surveillance is one of the most challenging areas in prostate cancer.

ProstaGene reduces:

> Overtreatment
> Missed aggressive disease
> Unnecessary prostatectomies
> Post-treatment regret
> Years of patient anxiety

This is what physicians care about most.
Because physicians prefer diagnostics rooted in mechanistic science

StromaGenesis’s biology is:

> Mechanistic
> Reproducible
> Clinically validated
> Directly linked to disease progression

Doctors trust what they can explain to patients.
Because ProstaGene requires no workflow changes

ProstaGene works on standard biopsy tissue, existing pathology workflows. With routine tissue processing. There is no retraining, no new equipment, and no extra burden.
Because ProstaGene provides therapeutic insight competitors cannot offer

StromaGenesis models:

> Treatment response
> Microenvironmental therapy resistance
> Stromal penetration factors
> Risk under therapy

This blurs the line between diagnostics and therapeutics — a major advantage.
Because StromaGenesis’s scientific leadership inspires physician confidence

With a founder of Dr. Pestell’s pedigree:

> Former NCI center director
> 158 H-index
> 120+ trials overseen
> Mechanistic biology pioneer

Physicians take StromaGenesis seriously on day one.
Because payers will eventually prefer StromaGenesis

Better triage = lower cost.

SG helps avoid unnecessary radical treatment, unnecessary imaging, or overtreatment cascades.

Financial incentives align with clinical incentives.

FAQ 7: Is there a real therapeutic upside, or is StromaGenesis just a diagnostic company? ▼

There is major therapeutic upside. StromaGenesis owns mechanistic biomarkers (CCR5, Cav-1) that regulate metastasis, fibrosis, immune evasion, and treatment resistance. StromaGenesis’s IP covers diagnostics, therapeutics, and companion diagnostic applications. This is a precision-oncology platform - not a single test.

Long Answer (Full Investor-Grade Version)

Because CCR5 and Cav-1 are mechanistic drivers of cancer - not passive markers

They regulate:

> Metastatic cell migration
> Stromal fibrosis
> ECM architecture
> Immune infiltration
> Drug resistance

This makes them therapeutic levers, not just diagnostic indicators.
Because StromaGenesis’s patents explicitly cover therapeutic applications

StromaGenesis’s IP includes:

> Treatment prediction
> Therapy selection
> Combination therapy optimization
> Microenvironmental targeting strategies

This is the same framework used by pharma-companion diagnostic partnerships.
Because StromaGenesis’s AI predicts therapy response

The algorithm can model:

> Who will benefit from intensified therapy
> Who will fail standard treatment
> Who has microenvironmental resistance
> Who needs combination therapy

This is the frontier of precision oncology.
Because StromaGenesis is positioned for companion diagnostic partnerships

Pharma collaborators want tools that stratify responders, improve trial efficiency, identify microenvironment-driven resistance, and enable combination therapy targeting.

StromaGenesis checks every box.
Because StromaGenesis’s biomarkers apply to multiple cancers

CCR5 and Cav-1 biology extends into:

> Breast
> Colon
> Pancreatic
> Lung
> Melanoma

This gives StromaGenesis a multi-indication therapeutic future.
Because StromaGenesis’s therapeutic platform elevates the company’s valuation

Diagnostics alone are valued at 5–8× revenue

Diagnostics + therapeutic potential trade at 10–25× revenue

or multi-billion-dollar acquisition multiples

StromaGenesis belongs in this category.
Because StromaGenesis can become a clinical decision engine - not just a lab test

Therapeutic integration moves SG into:

> Treatment planning
> Therapy matching
> Clinical trial enrichment
> Drug development support

This is the highest-value role in oncology diagnostics.